Category Archives: Myocardial Infarction

MONDAY, Nov. 23, 2020 (HealthDay News) -- Care for patients with type 2 myocardial infarction (MI) varies substantially, according to a research letter published online Nov. Continue reading →

This transcript has been edited for clarity. Dear colleagues, I'm Christoph Diener from the faculty of medicine at the University of Duisburg-Essen in Germany Continue reading →

Findings from a new study concluded that lipid-lowering lowering therapy is as effective in patients 75 years of age as in younger adults. Continue reading →

Global Myocardial Infarction Treatment Market 2025 Report Provides Porters Five Forces Analysis Illustrates the Potency of Buyers & Suppliers Operating in the Industry & the Quantitative Analysis of The Global Market from 2019 to 2025 is Provided to Determine the Market Potential. Myocardial Infarction Treatment Market Data and Acquisition Research Study with Trends and Opportunities 2019-2025 The study of Myocardial Infarction Treatment market is a compilation of the market of Myocardial Infarction Treatment broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Myocardial Infarction Treatment industry from a variety of data points that are collected through reputable and verified sources Continue reading →

Elevated levels of low-density lipoprotein cholesterol (LDL-C) in people between the ages of 70 and 100 years were found to be associated with a higher absolute risk for myocardial infarction (MI) and atherosclerotic cardiovascular disease, according to a study published in the Lancet. This was a systematic and meta-analysis in which data from the Copenhagen General Population Study (CGPS) of 91,131 people between the ages of 20 and 100 years who did not have atherosclerotic cardiovascular disease or diabetes at baseline and were not taking statin drugs were reviewed. Standard hospital assays were used to measure total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides, and direct LDL-C. Continue reading →

TOWSON, MD The University of Maryland St. Joseph Medical Center was included on a list of top 50 cardiovascular hospitals in the United States by Watson Health. The 2021 list is based on quality indicators and clinical outcomes for Medicare patients who received heart care in 2018 and 2019. Continue reading →

A whopping 93% of adult patients with type 2 diabetes (T2D)are at a high risk of experiencing a fatal acute myocardial infarction (AMI) or stroke, according to new research published in the European Journal of Preventive Cardiology. The study was focused on data out of Catalonia, Spain, but its findings will likely still grab the attention of researchersand patientsall over the world. Traditionally, cardiovascular risk in the region has been lower than in central and northern Europe or the U.S., co-author Manel Mata-Cases, PhD, of the Catalan Institute of Health in Barcelona, Spain, said in a statement Continue reading →

This article was originally published here Curr Probl Cardiol. Continue reading →

The 3-year results of the prospective mSTOPS study support the clinical value of early screening for atrial fibrillation (AF) and targeted detection in moderate-risk populations. Prof. Steven Steinhubl (Scripps Research Translational Institute, USA) presented the awaited 3-year results of the mSTOPS study of prospective screening for AF [1] Continue reading →

The addition of evolocumab to a statin regimen was found to lower the risk for complex coronary disease requiring revascularization in patients with stable atherosclerosis, according to study results published in the Journal of the American College of Cardiology. Evolocumab is an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). In the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER; ClinicalTrials.gov Identifier: NCT01764633) trial, 27,564 patients (ages, 40-85 years) with atherosclerosis, prior myocardial infarction (MI), non-hemorrhagic stroke, or symptomatic peripheral artery disease (PAD) were enrolled. Continue reading →